Corcept Therapeutics CORT Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Corcept Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The official record: Corcept Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Corcept Therapeutics's total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Corcept Therapeutics's total equity?
- Corcept Therapeutics (CORT) reported total equity of $637.99M in Q1 2026.
- How has Corcept Therapeutics's total equity changed year-over-year?
- Corcept Therapeutics's total equity decreased by 6.6% year-over-year, from $683.29M to $637.99M.
- What is the long-term trend for Corcept Therapeutics's total equity?
- Over 5 years (2020 to 2025), Corcept Therapeutics's total equity has grown at a 4.4% compound annual growth rate (CAGR), from $523.34M to $647.81M.
- What does total equity mean?
- The total value of the company belonging to shareholders after all debts are paid.
- How do you interpret total equity?
- Growth in equity generally signals increasing company value, provided it is driven by profitable operations rather than debt-funded buybacks.
- How does total equity compare across companies?
- Used to calculate Return on Equity (ROE) and compare leverage across peers.